Heart ultrasound study in multiple myeloma treated with RVd
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how a new heart ultrasound test can measure heart side effects and overall outcomes in people with multiple myeloma who are treated with the RVd drug combination. It may help doctors better understand heart risks during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have multiple myeloma (a blood cancer that affects plasma cells)
- You plan to receive RVd therapy (a three-drug combination: lenalidomide, bortezomib, and dexamethasone) during a hospital stay
- You can complete at least 3 to 4 cycles of treatment
- You do not have amyloidosis (protein buildup in organs) or serious heart conditions like heart attack, heart failure, atrial fibrillation, or prior heart surgery
- Your heart ultrasound images are clear enough for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to better monitor and manage heart health in people with multiple myeloma while they start a new treatment plan. It tests a heart risk check-in process with your care team to help catch and address any heart-related issues early.
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
This trial tests a new combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people who are older or frail and have just been diagnosed with multiple myeloma. It aims to see if this treatment can help control the disease better, especially if certain cancer cells are found in the blood.
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.